Research comparison
A side-by-side comparison of Tirzepatide and Semaglutide as they are characterised in the peer-reviewed research literature. Incretin-receptor metabolic research. Both compounds are supplied for in-vitro laboratory research only.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Research area | Metabolic Research | Metabolic Research |
| Sizes stocked | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg, 90mg, 100mg, 110mg, 120mg | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg |
| Reference | Full Tirzepatide page → | Full Semaglutide page → |
Tirzepatide is a synthetic 39-amino-acid peptide characterised in the literature as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Supplied as lyophilised powder for in-vitro research use only.
Semaglutide is a 31-amino-acid peptide characterised in the literature as an agonist at the glucagon-like peptide-1 (GLP-1) receptor, sharing approximately 94% sequence homology with native human GLP-1. Supplied as lyophilised powder for in-vitro research use only.
Both compounds are characterised in the research literature within incretin-receptor metabolic research. Researchers typically consult the primary peer-reviewed publications for each compound before selecting one for a specific experimental protocol. The two are frequently studied in parallel and occasionally cited together in comparative pharmacology reviews.
Both Tirzepatide and Semaglutide are supplied as lyophilised powder and reconstituted with bacteriostatic water using standard laboratory technique. For full reconstitution methodology see our Research Handling Guide, or compute resulting mg/ml concentrations with the Reconstitution Volume Calculator.
Every batch of both compounds is independently HPLC-verified by Janoshik Analytical at 99%+ purity. The lab report is supplied with every order and carries a unique verification key.